Published in Clin Dev Immunol on November 08, 2012
Shiga Toxin (Stx) Classification, Structure, and Function. Microbiol Spectr (2014) 0.99
Atypical HUS: time to take stock of current guidelines and outcome measures? Pediatr Nephrol (2013) 0.82
Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome. J Clin Immunol (2015) 0.76
Immunosuppressive Medications. Clin J Am Soc Nephrol (2015) 0.75
Overcoming technical challenges when treating atypical hemolytic uremic syndrome with therapeutic plasma exchange. Int J Nephrol Renovasc Dis (2013) 0.75
Atypical hemolytic-uremic syndrome. N Engl J Med (2009) 5.66
Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood (2006) 4.51
Complement regulators and inhibitory proteins. Nat Rev Immunol (2009) 4.46
Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int (1998) 4.03
Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int (2012) 3.99
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol (2010) 3.82
Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A (2006) 3.80
Atypical hemolytic uremic syndrome. Orphanet J Rare Dis (2011) 3.35
Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood (2008) 3.10
Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol (2007) 3.04
Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol (2006) 2.88
Inactivator of the third component of complement as an inhibitor in the properdin pathway. Proc Natl Acad Sci U S A (1972) 2.84
Familial haemolytic uraemic syndrome and an MCP mutation. Lancet (2003) 2.79
Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A (2003) 2.79
Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet (2003) 2.71
The membrane attack complex of complement. Annu Rev Immunol (1986) 2.57
Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am J Hum Genet (1999) 2.42
Activation of the complement system by antibody-antigen complexes: the classical pathway. Adv Protein Chem (1979) 2.39
The spectrum of complement alternative pathway-mediated diseases. Immunol Rev (2008) 2.16
Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet (2005) 2.06
The alternative pathway of complement. Springer Semin Immunopathol (1984) 2.01
Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol (2006) 1.82
Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis (2004) 1.71
Regulation of the complement membrane attack pathway. Crit Rev Immunol (1999) 1.66
Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol Immunol (2006) 1.64
The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. Hum Mutat (2007) 1.59
Variant-specific quantification of factor H in plasma identifies null alleles associated with atypical hemolytic uremic syndrome. Kidney Int (2010) 1.56
Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol (2010) 1.53
Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods (2011) 1.46
New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol (2010) 1.36
Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol (2008) 1.34
The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol (2008) 1.31
A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome. Neth J Med (2012) 1.30
Emerging roles and new functions of CD46. Springer Semin Immunopathol (2005) 1.16
Structure and function of complement C5 convertase enzymes. Biochem Soc Trans (2002) 1.15
The spectrum of phenotypes caused by variants in the CFH gene. Mol Immunol (2009) 1.13
Complement factor H genetic variant and age-related macular degeneration: effect size, modifiers and relationship to disease subtype. Int J Epidemiol (2012) 1.12
Complement factor I in health and disease. Mol Immunol (2011) 1.10
A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome. Blood (2011) 1.09
A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria, hypertension and chronic renal failure. Clin J Am Soc Nephrol (2009) 1.07
Complement factor H related proteins in immune diseases. Vaccine (2008) 1.07
Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS. Mol Immunol (2011) 1.06
A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome. J Immunol (2012) 0.99
Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome. Ann Hum Genet (2010) 0.97
Which came first, the lectin/classical pathway or the alternative pathway of complement? Immunobiology (2002) 0.94
Shiga toxin-associated hemolytic uremic syndrome: advances in pathogenesis and therapeutics. Curr Opin Nephrol Hypertens (2012) 0.94
Inhibiting complement activation on cells at the step of C3 cleavage. Vaccine (2008) 0.94
The lectin pathway of the complement system. Microbiol Immunol (1996) 0.94
Age-related penetrance of hereditary atypical hemolytic uremic syndrome. Ann Hum Genet (2011) 0.92
aHUS: a disorder with many risk factors. Blood (2010) 0.92
Multiple interactions of complement Factor H with its ligands in solution: a progress report. Adv Exp Med Biol (2010) 0.89
The lectin pathway of complement activation. Res Immunol (1996) 0.88
CD46 in innate and adaptive immunity: an update. Clin Exp Immunol (2011) 0.88
Conformational complexity of complement component C3. Adv Exp Med Biol (2006) 0.85
Fatal haemolytic uraemic syndrome and idiopathic hyperlipaemia in monozygotic twins. Arch Dis Child (1965) 0.84
Postpartum aHUS secondary to a genetic abnormality in factor H acquired through liver transplantation. Am J Transplant (2012) 0.79
Manifestation of atypical hemolytic uremic syndrome caused by novel mutations in MCP. Pediatr Nephrol (2011) 0.78
Do complement factor H 402Y and C7 M allotypes predispose to (typical) haemolytic uraemic syndrome? Int J Immunogenet (2011) 0.77
Atypical hemolytic uremic syndrome and mutation analysis of factor H gene in two Tunisian families. Int J Nephrol Renovasc Dis (2010) 0.76
A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A (2005) 13.44
Comprehensive genetic testing for hereditary hearing loss using massively parallel sequencing. Proc Natl Acad Sci U S A (2010) 3.85
Forty-six genes causing nonsyndromic hearing impairment: which ones should be analyzed in DNA diagnostics? Mutat Res (2008) 3.76
Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol (2005) 3.57
Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int (2009) 3.12
C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int (2012) 3.05
GJB2 mutations and degree of hearing loss: a multicenter study. Am J Hum Genet (2005) 2.63
Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int (2011) 2.61
Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat (2010) 2.44
SIX1 mutations cause branchio-oto-renal syndrome by disruption of EYA1-SIX1-DNA complexes. Proc Natl Acad Sci U S A (2004) 2.41
An international effort towards developing standards for best practices in analysis, interpretation and reporting of clinical genome sequencing results in the CLARITY Challenge. Genome Biol (2014) 1.95
Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol (2011) 1.92
A forward genetics screen in mice identifies recessive deafness traits and reveals that pejvakin is essential for outer hair cell function. J Neurosci (2007) 1.90
Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int (2012) 1.81
Prestin, a cochlear motor protein, is defective in non-syndromic hearing loss. Hum Mol Genet (2003) 1.80
Prevalence and evolutionary origins of the del(GJB6-D13S1830) mutation in the DFNB1 locus in hearing-impaired subjects: a multicenter study. Am J Hum Genet (2003) 1.79
Branchio-oto-renal syndrome: the mutation spectrum in EYA1 and its phenotypic consequences. Hum Mutat (2004) 1.77
Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol (2012) 1.70
Mutational spectrum of the WFS1 gene in Wolfram syndrome, nonsyndromic hearing impairment, diabetes mellitus, and psychiatric disease. Hum Mutat (2003) 1.67
Advancing genetic testing for deafness with genomic technology. J Med Genet (2013) 1.66
Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice. Am J Hum Genet (2008) 1.65
Transcriptional control of SLC26A4 is involved in Pendred syndrome and nonsyndromic enlargement of vestibular aqueduct (DFNB4). Am J Hum Genet (2007) 1.59
Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis (2010) 1.57
Frequency of Usher syndrome in two pediatric populations: Implications for genetic screening of deaf and hard of hearing children. Genet Med (2010) 1.56
Transcription factor SIX5 is mutated in patients with branchio-oto-renal syndrome. Am J Hum Genet (2007) 1.52
New treatment options for lymphangioma in infants and children. Ann Otol Rhinol Laryngol (2002) 1.50
Audioprofile-directed screening identifies novel mutations in KCNQ4 causing hearing loss at the DFNA2 locus. Genet Med (2008) 1.49
Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Nephrol (2010) 1.42
Case of progressive dysplasia concomitant with intralesional cidofovir administration for recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol (2005) 1.41
No evidence for association between the renin-angiotensin-aldosterone system and otosclerosis in a large Belgian-Dutch population. Otol Neurotol (2009) 1.40
Function and expression pattern of nonsyndromic deafness genes. Curr Mol Med (2009) 1.40
Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol (2011) 1.38
Mutations of the RDX gene cause nonsyndromic hearing loss at the DFNB24 locus. Hum Mutat (2007) 1.37
Mutations in a novel gene, TMIE, are associated with hearing loss linked to the DFNB6 locus. Am J Hum Genet (2002) 1.37
Deafness in the genomics era. Hear Res (2011) 1.37
Mutations in LOXHD1, an evolutionarily conserved stereociliary protein, disrupt hair cell function in mice and cause progressive hearing loss in humans. Am J Hum Genet (2009) 1.37
Loss-of-function mutations of ILDR1 cause autosomal-recessive hearing impairment DFNB42. Am J Hum Genet (2011) 1.37
Sensorineural deafness and male infertility: a contiguous gene deletion syndrome. J Med Genet (2006) 1.36
Branchio-oto-renal syndrome (BOR): novel mutations in the EYA1 gene, and a review of the mutational genetics of BOR. Hum Mutat (2008) 1.35
Branchio-oto-renal syndrome. Am J Med Genet A (2007) 1.34
Gipc3 mutations associated with audiogenic seizures and sensorineural hearing loss in mouse and human. Nat Commun (2011) 1.33
Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol (2013) 1.32
Pendred syndrome and DFNB4-mutation screening of SLC26A4 by denaturing high-performance liquid chromatography and the identification of eleven novel mutations. Am J Med Genet A (2004) 1.32
A claudin-9-based ion permeability barrier is essential for hearing. PLoS Genet (2009) 1.29
Inactivation of NADPH oxidase organizer 1 results in severe imbalance. Curr Biol (2006) 1.27
Advances in molecular and cellular therapies for hearing loss. Mol Ther (2007) 1.25
Causes of facial swelling in pediatric patients: correlation of clinical and radiologic findings. Radiographics (2006) 1.25
Genotype-phenotype correlations for SLC26A4-related deafness. Hum Genet (2007) 1.24
C3 glomerulonephritis associated with monoclonal gammopathy: a case series. Am J Kidney Dis (2013) 1.24
Mutations in the WFS1 gene that cause low-frequency sensorineural hearing loss are small non-inactivating mutations. Hum Genet (2002) 1.23
Genetics: advances in genetic testing for deafness. Curr Opin Pediatr (2012) 1.23
Recent advances in the molecular genetics of epilepsy. J Med Genet (2013) 1.21
Human male infertility caused by mutations in the CATSPER1 channel protein. Am J Hum Genet (2009) 1.19
The WFS1 gene, responsible for low frequency sensorineural hearing loss and Wolfram syndrome, is expressed in a variety of inner ear cells. Histochem Cell Biol (2003) 1.17
SIX1 mutation screening in 247 branchio-oto-renal syndrome families: a recurrent missense mutation associated with BOR. Hum Mutat (2008) 1.17
Hearing loss in Union Army veterans from 1862 to 1920. Laryngoscope (2004) 1.16
Mutations in the first MyTH4 domain of MYO15A are a common cause of DFNB3 hearing loss. Laryngoscope (2009) 1.16
Mutations of KCNJ10 together with mutations of SLC26A4 cause digenic nonsyndromic hearing loss associated with enlarged vestibular aqueduct syndrome. Am J Hum Genet (2009) 1.16
Comparative linkage analysis and visualization of high-density oligonucleotide SNP array data. BMC Genet (2005) 1.14
Mutation in the COCH gene is associated with superior semicircular canal dehiscence. Am J Med Genet A (2009) 1.14
A catechol-O-methyltransferase that is essential for auditory function in mice and humans. Proc Natl Acad Sci U S A (2008) 1.13
DFNA8/12 caused by TECTA mutations is the most identified subtype of nonsyndromic autosomal dominant hearing loss. Hum Mutat (2011) 1.13
The genetics of otosclerosis. Hear Res (2009) 1.13
Clinical features and outcomes of 98 children and adults with dense deposit disease. Pediatr Nephrol (2011) 1.13
A contemporary review of AudioGene audioprofiling: a machine-based candidate gene prediction tool for autosomal dominant nonsyndromic hearing loss. Laryngoscope (2009) 1.12
A genome-wide analysis identifies genetic variants in the RELN gene associated with otosclerosis. Am J Hum Genet (2009) 1.11
Solution-based targeted genomic enrichment for precious DNA samples. BMC Biotechnol (2012) 1.11
Efficacy and safety of OK-432 immunotherapy of lymphatic malformations. Laryngoscope (2009) 1.10
In vitro and in vivo suppression of GJB2 expression by RNA interference. Hum Mol Genet (2005) 1.10
A novel splice site mutation in EYA4 causes DFNA10 hearing loss. Am J Med Genet A (2007) 1.10
GJB2 mutations: passage through Iran. Am J Med Genet A (2005) 1.09
Performance of cochlear implant recipients with GJB2-related deafness. Am J Med Genet (2002) 1.09
The coding polymorphism T263I in TGF-beta1 is associated with otosclerosis in two independent populations. Hum Mol Genet (2007) 1.08
Association of bone morphogenetic proteins with otosclerosis. J Bone Miner Res (2008) 1.07
Treatment of lymphangiomas with OK-432 (Picibanil) sclerotherapy: a prospective multi-institutional trial. Arch Otolaryngol Head Neck Surg (2002) 1.07
Clinical aspects of hereditary hearing loss. Genet Med (2007) 1.06
Selective cochlear degeneration in mice lacking the F-box protein, Fbx2, a glycoprotein-specific ubiquitin ligase subunit. J Neurosci (2007) 1.06
Genetic heterogeneity of deafness phenotypes linked to DFNA4. Am J Med Genet A (2005) 1.05
TBC1D24 mutation causes autosomal-dominant nonsyndromic hearing loss. Hum Mutat (2014) 1.05
Genomic rearrangements of EYA1 account for a large fraction of families with BOR syndrome. Eur J Hum Genet (2002) 1.04
Soluble CR1 therapy improves complement regulation in C3 glomerulopathy. J Am Soc Nephrol (2013) 1.04
Genetic male infertility and mutation of CATSPER ion channels. Eur J Hum Genet (2010) 1.03
Association of a novel complement factor H mutation with severe crescentic and necrotizing glomerulonephritis. Am J Kidney Dis (2012) 1.03
GJB2: the spectrum of deafness-causing allele variants and their phenotype. Hum Mutat (2004) 1.03
Mutations in TMC1 are a common cause of DFNB7/11 hearing loss in the Iranian population. Ann Otol Rhinol Laryngol (2010) 1.02
An integrated genetic and functional analysis of the role of type II transmembrane serine proteases (TMPRSSs) in hearing loss. Hum Mutat (2008) 1.02
The role of connexins in human disease. Ear Hear (2003) 1.02
Mice lacking Dfna5 show a diverging number of cochlear fourth row outer hair cells. Neurobiol Dis (2005) 1.01
Identification of three novel TECTA mutations in Iranian families with autosomal recessive nonsyndromic hearing impairment at the DFNB21 locus. Am J Med Genet A (2007) 1.00
A novel mutation in the complement factor B gene (CFB) and atypical hemolytic uremic syndrome. Pediatr Nephrol (2010) 1.00
Nonsyndromic hearing loss. Ear Hear (2003) 1.00
H-type congenital tracheoesophageal fistula: University Of Iowa experience 1985 to 2005. Ann Otol Rhinol Laryngol (2007) 1.00
Cochlear implantation in deafness-dystonia-optic neuronopathy (DDON) syndrome. Int J Pediatr Otorhinolaryngol (2007) 0.99
Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. Laryngoscope (2004) 0.99
Screening for MYO15A gene mutations in autosomal recessive nonsyndromic, GJB2 negative Iranian deaf population. Am J Med Genet A (2012) 0.99
A novel TECTA mutation confirms the recognizable phenotype among autosomal recessive hearing impairment families. Int J Pediatr Otorhinolaryngol (2007) 0.99
Deletion of and novel missense mutation in POU3F4 in 2 families segregating X-linked nonsyndromic deafness. Arch Otolaryngol Head Neck Surg (2005) 0.98
Cochlear expression of a dominant-negative GJB2R75W construct delivered through the round window membrane in mice. Neurosci Res (2007) 0.97
The effect of GJB2 allele variants on performance after cochlear implantation. Laryngoscope (2003) 0.96
High frequency of the p.R34X mutation in the TMC1 gene associated with nonsyndromic hearing loss is due to founder effects. Genet Test Mol Biomarkers (2010) 0.96